|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Aerovate Therapeutics, Inc. (AVTE) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
27,670,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aerovate Therapeutics is a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Co.'s initial focus is on improving AV-101, its dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. AV-101, delivered using a dry powder inhaler, is designed to provide lung concentrations at or above those observed with the oral dose while limiting systemic levels of the drug.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
198,525 |
283,422 |
343,887 |
1,083,676 |
| Total Sell Value |
$5,199,454 |
$6,632,651 |
$7,649,183 |
$16,638,542 |
| Total People Sold |
6 |
7 |
7 |
8 |
| Total Sell Transactions |
25 |
38 |
50 |
111 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Niven Ralph |
CHIEF SCIENTIFIC OFFICER |
• – – |
2024-01-05 |
4 |
OE |
$1.74 |
$9,284 |
D/D |
4,600 |
6,209 |
|
- |
|
| Gillies Hunter |
CHIEF MEDICAL OFFICER |
• – – |
2023-12-27 |
4 |
AS |
$24.50 |
$3,063 |
D/D |
(125) |
3,251 |
|
- |
|
| Gillies Hunter |
CHIEF MEDICAL OFFICER |
• – – |
2023-12-27 |
4 |
OE |
$2.14 |
$268 |
D/D |
125 |
3,376 |
|
- |
|
| Gillies Hunter |
CHIEF MEDICAL OFFICER |
• – – |
2023-12-20 |
4 |
AS |
$19.50 |
$78,000 |
D/D |
(4,000) |
3,251 |
|
- |
|
| Gillies Hunter |
CHIEF MEDICAL OFFICER |
• – – |
2023-12-14 |
4 |
AS |
$19.50 |
$192,992 |
D/D |
(9,897) |
3,251 |
|
- |
|
| Gillies Hunter |
CHIEF MEDICAL OFFICER |
• – – |
2023-12-14 |
4 |
OE |
$1.74 |
$17,221 |
D/D |
9,897 |
13,148 |
|
- |
|
| Gillies Hunter |
CHIEF MEDICAL OFFICER |
• – – |
2023-12-13 |
4 |
OE |
$1.74 |
$6,960 |
D/D |
4,000 |
7,251 |
|
- |
|
| Gillies Hunter |
CHIEF MEDICAL OFFICER |
• – – |
2023-12-13 |
4 |
AS |
$19.50 |
$41,009 |
D/D |
(2,103) |
3,251 |
|
- |
|
| Gillies Hunter |
CHIEF MEDICAL OFFICER |
• – – |
2023-12-13 |
4 |
OE |
$1.74 |
$3,659 |
D/D |
2,103 |
5,354 |
|
- |
|
| Dake Benjamin T |
SEE REMARKS |
• – – |
2023-12-06 |
4 |
AS |
$16.11 |
$165,628 |
D/D |
(10,283) |
1,291 |
|
- |
|
| Dake Benjamin T |
SEE REMARKS |
• – – |
2023-12-06 |
4 |
OE |
$1.74 |
$21,041 |
D/D |
10,283 |
11,574 |
|
- |
|
| Niven Ralph |
CHIEF SCIENTIFIC OFFICER |
• – – |
2023-12-05 |
4 |
AS |
$16.30 |
$74,996 |
D/D |
(4,600) |
1,609 |
|
- |
|
| Niven Ralph |
CHIEF SCIENTIFIC OFFICER |
• – – |
2023-12-05 |
4 |
OE |
$1.74 |
$9,284 |
D/D |
4,600 |
6,209 |
|
- |
|
| Dake Benjamin T |
SEE REMARKS |
• – – |
2023-11-27 |
4 |
AS |
$16.24 |
$203,237 |
D/D |
(12,517) |
1,291 |
|
- |
|
| Dake Benjamin T |
SEE REMARKS |
• – – |
2023-11-27 |
4 |
OE |
$1.74 |
$25,821 |
D/D |
12,517 |
13,808 |
|
- |
|
| Dake Benjamin T |
SEE REMARKS |
• – – |
2023-11-24 |
4 |
AS |
$15.74 |
$78,548 |
D/D |
(4,990) |
1,291 |
|
- |
|
| Dake Benjamin T |
SEE REMARKS |
• – – |
2023-11-24 |
4 |
OE |
$2.14 |
$10,679 |
D/D |
4,990 |
6,281 |
|
- |
|
| Niven Ralph |
CHIEF SCIENTIFIC OFFICER |
• – – |
2023-11-22 |
4 |
AS |
$15.00 |
$207,000 |
D/D |
(13,800) |
1,609 |
|
- |
|
| Niven Ralph |
CHIEF SCIENTIFIC OFFICER |
• – – |
2023-11-22 |
4 |
OE |
$1.74 |
$27,852 |
D/D |
13,800 |
15,409 |
|
- |
|
| Dake Benjamin T |
SEE REMARKS |
• – – |
2023-11-22 |
4 |
AS |
$15.17 |
$142,359 |
D/D |
(9,382) |
1,291 |
|
- |
|
| Dake Benjamin T |
SEE REMARKS |
• – – |
2023-11-22 |
4 |
OE |
$1.74 |
$19,113 |
D/D |
9,382 |
10,673 |
|
- |
|
| Dake Benjamin T |
SEE REMARKS |
• – – |
2023-09-07 |
4 |
AS |
$15.01 |
$450 |
D/D |
(30) |
1,291 |
|
- |
|
| Dake Benjamin T |
SEE REMARKS |
• – – |
2023-09-07 |
4 |
OE |
$2.14 |
$64 |
D/D |
30 |
1,321 |
|
- |
|
| Dake Benjamin T |
SEE REMARKS |
• – – |
2023-09-06 |
4 |
AS |
$15.06 |
$59,187 |
D/D |
(3,931) |
1,291 |
|
- |
|
| Dake Benjamin T |
SEE REMARKS |
• – – |
2023-09-06 |
4 |
OE |
$1.74 |
$7,447 |
D/D |
3,931 |
5,222 |
|
- |
|
225 Records found
|
|
Page 3 of 9 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
